Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Operating Margin
Recordati Industria Chimica e Farmaceutica SpA
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IT |
|
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
|
9.5B EUR |
28%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
685.8B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
362.5B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
196.2B CHF |
32%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
176.4B CHF |
32%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
205.6B USD |
36%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
155.9B GBP |
23%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
128.2B USD |
25%
|
Recordati Industria Chimica e Farmaceutica SpA
Glance View
Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs. Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Recordati Industria Chimica e Farmaceutica SpA's most recent financial statements, the company has Operating Margin of 28.1%.
You don't have any saved screeners yet